US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US4326525A
(en)
|
1980-10-14 |
1982-04-27 |
Alza Corporation |
Osmotic device that improves delivery properties of agent in situ
|
US5364620A
(en)
|
1983-12-22 |
1994-11-15 |
Elan Corporation, Plc |
Controlled absorption diltiazem formulation for once daily administration
|
US5023252A
(en)
|
1985-12-04 |
1991-06-11 |
Conrex Pharmaceutical Corporation |
Transdermal and trans-membrane delivery of drugs
|
US5001139A
(en)
|
1987-06-12 |
1991-03-19 |
American Cyanamid Company |
Enchancers for the transdermal flux of nivadipine
|
US4992445A
(en)
|
1987-06-12 |
1991-02-12 |
American Cyanamid Co. |
Transdermal delivery of pharmaceuticals
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4902514A
(en)
|
1988-07-21 |
1990-02-20 |
Alza Corporation |
Dosage form for administering nilvadipine for treating cardiovascular symptoms
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
BR9916223A
(pt)
|
1998-12-17 |
2001-09-04 |
Hoffmann La Roche |
4-ariloxindóis como inibidores de cinases de proteìna jnk
|
JP4619545B2
(ja)
|
1999-03-17 |
2011-01-26 |
アストラゼネカ アクチボラグ |
アミド誘導体
|
JP2001302667A
(ja)
|
2000-04-28 |
2001-10-31 |
Bayer Ag |
イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
DK1628685T3
(da)
|
2003-04-25 |
2011-03-21 |
Gilead Sciences Inc |
Antivirale phosphonatanaloge
|
WO2005035520A1
(en)
|
2003-10-03 |
2005-04-21 |
Portola Pharmaceuticals, Inc. |
Substituted isoquinolinones
|
BRPI0418112A
(pt)
|
2003-12-23 |
2007-04-17 |
Novartis Ag |
inibidores de p-38 quinase bicìclico heterocìclicos
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
GB0412769D0
(en)
|
2004-06-08 |
2004-07-07 |
Novartis Ag |
Organic compounds
|
JP2008504294A
(ja)
|
2004-06-25 |
2008-02-14 |
アムジエン・インコーポレーテツド |
サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール
|
EA019419B1
(ru)
|
2004-07-27 |
2014-03-31 |
Джилид Сайэнс, Инк. |
Фосфонатные аналоги соединений ингибиторов вич, фармацевтическая композиция и набор, их включающие, и способ лечения нарушений, ассоциированных с вич
|
WO2006044687A2
(en)
|
2004-10-15 |
2006-04-27 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
WO2007032371A1
(ja)
|
2005-09-14 |
2007-03-22 |
Dainippon Sumitomo Pharma Co., Ltd. |
摂食調節剤としてのオキシインドール誘導体
|
US20070087988A1
(en)
|
2005-09-30 |
2007-04-19 |
New York University |
Hematopoietic progenitor kinase 1 for modulation of an immune response
|
TW200736260A
(en)
|
2005-11-10 |
2007-10-01 |
Smithkline Beecham Corp |
Inhibitors of Akt activity
|
TWI399377B
(zh)
|
2006-07-07 |
2013-06-21 |
Gilead Sciences Inc |
類鐸受體7之調節劑
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
WO2008046083A2
(en)
|
2006-10-12 |
2008-04-17 |
Xenon Pharmaceuticals Inc. |
Use of oxindole compounds as therapeutic agents
|
WO2008078091A1
(en)
|
2006-12-22 |
2008-07-03 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
KR20090094338A
(ko)
|
2006-12-27 |
2009-09-04 |
사노피-아벤티스 |
치환된 이소퀴놀린 및 이소퀴놀리논 유도체
|
MX2009005825A
(es)
|
2006-12-27 |
2009-06-16 |
Sanofi Aventis |
Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
CN101679423A
(zh)
|
2007-04-03 |
2010-03-24 |
阵列生物制药公司 |
作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
|
DE102007019690A1
(de)
|
2007-04-26 |
2008-10-30 |
Bayer Healthcare Ag |
Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
|
US7968544B2
(en)
|
2007-06-29 |
2011-06-28 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
EP2019100A1
(en)
|
2007-07-19 |
2009-01-28 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
|
EP2020405A1
(en)
|
2007-07-30 |
2009-02-04 |
Santhera Pharmaceuticals (Schweiz) AG |
Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
|
CN101842114A
(zh)
|
2007-08-02 |
2010-09-22 |
阿雷斯托生物科学股份有限公司 |
治疗和诊断纤维化、肿瘤侵入、血管生成和转移的方法和组合物
|
UA100250C2
(uk)
|
2007-11-16 |
2012-12-10 |
Гілеад Сайнсіз, Інк. |
Інгібітори реплікації вірусу імунодефіциту людини
|
RU2010129690A
(ru)
|
2007-12-19 |
2012-01-27 |
Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) |
Бициклические гетероциклические производные
|
TW200938542A
(en)
|
2008-02-01 |
2009-09-16 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
PE20110308A1
(es)
|
2008-07-08 |
2011-06-10 |
Incyte Corp |
1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
|
CA2732437C
(en)
|
2008-08-01 |
2017-11-21 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
CA2734802C
(en)
|
2008-08-22 |
2016-05-31 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
US8642583B2
(en)
|
2008-10-30 |
2014-02-04 |
Janssen Pharmaceutica Nv |
Serotonin receptor modulators
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
CN102272134B
(zh)
|
2008-12-09 |
2013-10-16 |
吉里德科学公司 |
Toll样受体调节剂
|
US8338441B2
(en)
|
2009-05-15 |
2012-12-25 |
Gilead Sciences, Inc. |
Inhibitors of human immunodeficiency virus replication
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
CN102574847A
(zh)
|
2009-07-30 |
2012-07-11 |
Irm责任有限公司 |
作为syk激酶抑制剂的化合物和组合物
|
RU2593261C2
(ru)
|
2009-08-18 |
2016-08-10 |
Вентиркс Фармасьютикалс, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобных рецепторов
|
CN102781933B
(zh)
|
2009-08-18 |
2016-01-20 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
NZ598933A
(en)
|
2009-10-22 |
2013-04-26 |
Gilead Sciences Inc |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
WO2011097513A1
(en)
|
2010-02-04 |
2011-08-11 |
Gilead Biologics, Inc |
Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
US9162981B2
(en)
|
2010-03-23 |
2015-10-20 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
WO2011130146A1
(en)
|
2010-04-14 |
2011-10-20 |
Array Biopharma Inc. |
5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
US20130165489A1
(en)
|
2010-05-03 |
2013-06-27 |
The Trustees Of The University Of Pennsylvania |
Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
WO2011152351A1
(ja)
|
2010-05-31 |
2011-12-08 |
小野薬品工業株式会社 |
プリノン誘導体
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
WO2012003498A1
(en)
|
2010-07-02 |
2012-01-05 |
Gilead Sciences, Inc. |
2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
|
PE20130385A1
(es)
|
2010-07-02 |
2013-03-30 |
Gilead Sciences Inc |
Derivados del acido naft-2-ilacetico para tratar el sida
|
TW201211028A
(en)
|
2010-08-10 |
2012-03-16 |
Dainippon Sumitomo Pharma Co |
Fused ring pyrrolidine derivatives
|
AP2016009448A0
(en)
|
2010-08-27 |
2016-09-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
CN103237549A
(zh)
|
2010-10-01 |
2013-08-07 |
帆德制药股份有限公司 |
过敏性疾病的治疗方法
|
ES2616449T3
(es)
|
2010-10-01 |
2017-06-13 |
Ventirx Pharmaceuticals, Inc. |
Uso terapéutico de un agonista de TLR y terapia de combinación
|
SG10201510092QA
(en)
|
2010-12-09 |
2016-01-28 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
MX348935B
(es)
|
2011-01-12 |
2017-07-03 |
Ventirx Pharmaceuticals Inc |
Benzoazepinas sustituidas como moduladores de receptores tipo toll.
|
HUE032036T2
(en)
|
2011-01-12 |
2017-08-28 |
Ventirx Pharmaceuticals Inc |
Toll-type receptor modulator substituted benzodiazepines
|
WO2012097479A1
(en)
|
2011-01-21 |
2012-07-26 |
Abbott Laboratories |
Bicyclic inhibitors of anaphastic lymphoma kinase
|
WO2012101064A1
(en)
|
2011-01-28 |
2012-08-02 |
Novartis Ag |
N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
|
AU2012214394B2
(en)
|
2011-02-12 |
2016-08-11 |
Globeimmune, Inc. |
Yeast-based therapeutic for chronic hepatitis B infection
|
JP2014507458A
(ja)
|
2011-03-11 |
2014-03-27 |
グラクソ グループ リミテッド |
Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
|
KR102058946B1
(ko)
|
2011-04-08 |
2019-12-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
EA024952B1
(ru)
|
2011-04-21 |
2016-11-30 |
Джилид Сайэнс, Инк. |
Бензотиазолы и их применение для лечения вич-инфекции
|
ME02986B
(me)
|
2011-05-18 |
2018-10-20 |
Janssen Sciences Ireland Uc |
Derivati hinazolina za tretman viralnih infekcija i drugih bolesтi
|
US9096642B2
(en)
|
2011-06-08 |
2015-08-04 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
AU2012278976B2
(en)
|
2011-07-06 |
2017-05-11 |
Gilead Sciences, Inc. |
Compounds for the treatment of HIV
|
CN102863512B
(zh)
|
2011-07-07 |
2016-04-20 |
上海泓博智源医药技术有限公司 |
抗病毒化合物
|
DE102011080362A1
(de)
|
2011-08-03 |
2013-02-07 |
Robert Bosch Gmbh |
Elektrisches Kontaktelement mit Rastlanze für ein Steckergehäuse
|
US9187462B2
(en)
|
2011-08-04 |
2015-11-17 |
Array Biopharma Inc. |
Substituted quinazolines as serine/threonine kinase inhibitors
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
EP2763994A4
(en)
|
2011-10-04 |
2015-08-26 |
Gilead Calistoga Llc |
NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
|
CN103987713A
(zh)
|
2011-10-12 |
2014-08-13 |
阵列生物制药公司 |
5,7-取代的咪唑并[1,2-c]嘧啶
|
RU2615999C2
(ru)
|
2011-11-29 |
2017-04-12 |
Оно Фармасьютикал Ко., Лтд. |
Гидрохлорид производного пуринона
|
WO2013091096A1
(en)
|
2011-12-20 |
2013-06-27 |
Boehringer Ingelheim International Gmbh |
Condensed triclyclic compounds as inhibitors of hiv replication
|
EA026368B1
(ru)
|
2011-12-21 |
2017-03-31 |
Новира Терапьютикс, Инк. |
Противовирусные агенты против гепатита в
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
AU2013218072B2
(en)
|
2012-02-08 |
2017-08-31 |
Janssen Sciences Ireland Uc |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
US9045493B2
(en)
|
2012-02-09 |
2015-06-02 |
Merck Patent Gmbh |
Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
|
WO2013130660A1
(en)
|
2012-02-28 |
2013-09-06 |
Amgen Inc. |
Amides as pim inhibitors
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
KR20140142736A
(ko)
|
2012-03-29 |
2014-12-12 |
오리진 디스커버리 테크놀로지스 리미티드 |
인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물
|
EP2831060B1
(en)
|
2012-03-31 |
2016-05-04 |
F.Hoffmann-La Roche Ag |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
KR20150002573A
(ko)
|
2012-04-20 |
2015-01-07 |
길리애드 사이언시즈, 인코포레이티드 |
벤조티아졸-6-일 아세트산 유도체 및 hiv 감염을 치료하기 위한 이의 용도
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
NZ724616A
(en)
|
2012-06-08 |
2018-06-29 |
Gilead Sciences Inc |
Macrocyclic inhibitors of flaviviridae viruses
|
WO2013185103A1
(en)
|
2012-06-08 |
2013-12-12 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
WO2014023813A1
(en)
|
2012-08-10 |
2014-02-13 |
Janssen R&D Ireland |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
SG10201709133QA
(en)
|
2012-08-28 |
2017-12-28 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
HUE031400T2
(en)
|
2012-08-28 |
2017-07-28 |
Janssen Sciences Ireland Uc |
Condensed bicyclic sulfamoyl derivatives and their use as medicaments for the treatment of hepatitis B
|
AU2013311705A1
(en)
|
2012-09-10 |
2015-02-05 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
TW201427995A
(zh)
|
2012-09-24 |
2014-07-16 |
Gilead Sciences Inc |
抗ddr1抗體
|
EP3150582A1
(en)
|
2012-10-02 |
2017-04-05 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
HUE037064T2
(hu)
|
2012-10-10 |
2018-08-28 |
Janssen Sciences Ireland Uc |
Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére
|
KR101268466B1
(ko)
|
2012-11-12 |
2013-06-04 |
유병수 |
사축형 윈드 터빈
|
JP6297055B2
(ja)
|
2012-11-16 |
2018-03-20 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染症の治療のための複素環置換2−アミノ−キナゾリン誘導体
|
EP3763367A1
(en)
|
2012-12-06 |
2021-01-13 |
Celgene Quanticel Research, Inc. |
Pyridine-pyrazole derivatives as histone demethylase inhibitors
|
ES2658597T3
(es)
|
2012-12-19 |
2018-03-12 |
Celgene Quanticel Research, Inc. |
Inhibidores de histona desmetilasa
|
AU2013361694B2
(en)
|
2012-12-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
MD4736C1
(ro)
|
2012-12-21 |
2021-07-31 |
Gilead Sciences, Inc. |
Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
|
TW201437203A
(zh)
|
2012-12-21 |
2014-10-01 |
Gilead Calistoga Llc |
磷脂醯肌醇3-激酶之抑制劑
|
BR112015014968A2
(pt)
|
2012-12-21 |
2017-07-11 |
Quanticel Pharmaceuticals Inc |
inibidores de histona-desmetilase
|
JP6125663B2
(ja)
|
2012-12-21 |
2017-05-10 |
ギリアード カリストガ エルエルシー |
ホスファチジルイノシトール3−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
|
MX2015008467A
(es)
|
2012-12-27 |
2015-09-23 |
Japan Tobacco Inc |
Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana.
|
CN103110932B
(zh)
|
2013-01-24 |
2015-08-19 |
北京大学第三医院 |
一种hip-55的新用途
|
CN103114087B
(zh)
|
2013-01-24 |
2015-05-06 |
北京大学第三医院 |
一种rna及其在心血管系统疾病中的应用
|
EP2958900B1
(en)
|
2013-02-21 |
2019-04-10 |
Janssen Sciences Ireland Unlimited Company |
2-aminopyrimidine derivatives for the treatment of viral infections
|
SG10201707027SA
(en)
|
2013-02-27 |
2017-09-28 |
Epitherapeutics Aps |
Inhibitors of histone demethylases
|
AU2014222641B2
(en)
|
2013-02-28 |
2018-03-15 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
CA2903473A1
(en)
|
2013-03-12 |
2014-10-09 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
US9187454B2
(en)
|
2013-03-13 |
2015-11-17 |
Boston Biomedical, Inc. |
Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
|
MX2015011898A
(es)
|
2013-03-13 |
2016-05-05 |
Genentech Inc |
Compuestos de pirazolo y usos de los mismos.
|
JP6276378B2
(ja)
|
2013-03-14 |
2018-02-07 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
JP6332654B2
(ja)
|
2013-03-15 |
2018-05-30 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
JP6419155B2
(ja)
|
2013-04-03 |
2018-11-07 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
SI2997019T1
(sl)
|
2013-05-17 |
2018-12-31 |
Janssen Sciences Ireland Uc, |
Derivati sulfamoiliofenamida in njihova uporaba kot zdravila za zdravljenje hepatitisa B
|
TW201512193A
(zh)
|
2013-05-17 |
2015-04-01 |
Hoffmann La Roche |
用於治療及防治b型肝炎病毒感染之新穎6-橋聯雜芳基二氫嘧啶
|
SI3008053T1
(en)
|
2013-06-14 |
2018-06-29 |
Gilead Calistoga Llc |
PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
|
WO2014202493A1
(en)
|
2013-06-19 |
2014-12-24 |
F. Hoffmann-La Roche Ag |
Indolin-2-one or pyrrolo-pyridin/pyrimidin-2-one derivatives
|
PL3024819T3
(pl)
|
2013-07-25 |
2018-08-31 |
Janssen Sciences Ireland Uc |
Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
|
CN105492446B
(zh)
|
2013-07-30 |
2018-08-03 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
|
PT3027601T
(pt)
*
|
2013-07-31 |
2018-01-08 |
Gilead Sciences Inc |
Inibidores de syk
|
JP2016527303A
(ja)
|
2013-08-05 |
2016-09-08 |
ケンブリッジ エンタープライズ リミテッド |
がん免疫療法におけるcxcr4シグナル伝達の阻害
|
US10471139B2
(en)
|
2013-08-15 |
2019-11-12 |
The University Of Kansas |
Toll-like receptor agonists
|
CA2923184A1
(en)
|
2013-09-04 |
2015-03-12 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
JP2016532711A
(ja)
|
2013-09-06 |
2016-10-20 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
免疫調節剤としての1,3,4−オキサジアゾール及び1,3,4−チアジアゾールの誘導体
|
KR20160075506A
(ko)
|
2013-09-06 |
2016-06-29 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서 사이클릭 펩티도미메틱 화합물
|
PL3363790T3
(pl)
|
2013-09-06 |
2020-07-27 |
Aurigene Discovery Technologies Limited |
Pochodne 1,2,4-oksadiazolu jako immunomodulatory
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
DK3043865T3
(da)
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
JP6483666B2
(ja)
|
2013-10-14 |
2019-03-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
選択的に置換されたキノリン化合物
|
MY192489A
(en)
|
2013-10-14 |
2022-08-23 |
Eisai R&D Man Co Ltd |
Selectively substituted quinoline compounds
|
ES2655518T3
(es)
|
2013-10-23 |
2018-02-20 |
Janssen Sciences Ireland Uc |
Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B
|
US9115113B2
(en)
|
2013-11-14 |
2015-08-25 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9801880B2
(en)
|
2013-12-02 |
2017-10-31 |
Bergenbio As |
Use of kinase inhibitors
|
CN105992766A
(zh)
|
2013-12-13 |
2016-10-05 |
武田药品工业株式会社 |
作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
|
CA2932351A1
(en)
|
2013-12-13 |
2015-06-18 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
JP6878004B2
(ja)
|
2013-12-13 |
2021-05-26 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
リンパ形質細胞性リンパ腫を処置する方法
|
WO2015095780A1
(en)
|
2013-12-20 |
2015-06-25 |
The University Of Kansas |
Toll-like receptor 8 agonists
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
EP3099685B1
(en)
|
2014-01-30 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
US20170037125A1
(en)
|
2014-02-04 |
2017-02-09 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
CN105980378B
(zh)
|
2014-02-06 |
2019-09-27 |
爱尔兰詹森科学公司 |
氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
|
EP3114144A1
(en)
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
SI3114128T1
(sl)
|
2014-03-07 |
2019-04-30 |
F. Hoffmann-La Roche Ag |
Novi 6-spojeni heteroarildihidropirimidini za zdravljenje in preprečevanje okužbe z virusom hepatitisa B
|
US20170008896A1
(en)
|
2014-03-19 |
2017-01-12 |
Boehringer Ingelheim International Gmbh |
Heteroaryl syk inhibitors
|
CN106458974B
(zh)
|
2014-03-24 |
2019-07-16 |
广东众生药业股份有限公司 |
作为smo抑制剂的喹啉衍生物
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
US20170029774A1
(en)
|
2014-04-10 |
2017-02-02 |
Seattle Children's Hospital (dba Seattle Children' Research Institute) |
Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
KR101905292B1
(ko)
|
2014-04-22 |
2018-11-21 |
에프. 호프만-라 로슈 아게 |
4-아미노-이미다조퀴놀린 화합물
|
JP6541689B2
(ja)
|
2014-05-01 |
2019-07-10 |
ノバルティス アーゲー |
Toll様受容体7アゴニストとしての化合物および組成物
|
SG11201608161VA
(en)
|
2014-05-01 |
2016-11-29 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
CA2948080A1
(en)
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
SG11201609770TA
(en)
|
2014-05-23 |
2016-12-29 |
Eisai R&D Man Co Ltd |
Combination therapies for the treatment of cancer
|
US10987322B2
(en)
|
2014-06-06 |
2021-04-27 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
WO2016004305A2
(en)
|
2014-07-02 |
2016-01-07 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
WO2016019232A1
(en)
|
2014-08-01 |
2016-02-04 |
John Vasilakos |
Methods and therapeutic combinations for treating tumors
|
RU2664329C1
(ru)
|
2014-08-14 |
2018-08-16 |
Ф. Хоффманн-Ля Рош Аг |
Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
|
DK3190113T3
(da)
|
2014-08-15 |
2021-06-07 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
|
EP3398948A3
(en)
|
2014-08-22 |
2018-12-05 |
Janus Biotherapeutics, Inc. |
2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
US9802941B2
(en)
|
2014-08-27 |
2017-10-31 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
MA40132B1
(fr)
|
2014-09-11 |
2019-04-30 |
Bristol Myers Squibb Co |
Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
|
US20170298443A1
(en)
|
2014-09-25 |
2017-10-19 |
Moffitt Genetics Corporation |
Prognostic tumor biomarkers
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6783230B2
(ja)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物
|
CN107001386A
(zh)
|
2014-10-11 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的化合物
|
TR201900148T4
(tr)
|
2014-10-31 |
2019-02-21 |
Genoscience Pharma Sas |
Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
JP6702991B2
(ja)
|
2014-11-03 |
2020-06-03 |
ジェネンテック, インコーポレイテッド |
T細胞免疫サブセットを検出するためのアッセイ及びその使用の方法
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
MX2017005462A
(es)
|
2014-11-05 |
2017-07-28 |
Flexus Biosciences Inc |
Agentes inmunorreguladores.
|
EP3218377B1
(en)
|
2014-11-13 |
2022-04-13 |
GlaxoSmithKline Biologicals SA |
Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA2969456A1
(en)
|
2014-12-03 |
2016-06-09 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
SI3230298T1
(sl)
|
2014-12-08 |
2021-04-30 |
F. Hoffmann-La Roche Ag |
Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom
|
WO2016100236A2
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
US20190055235A1
(en)
|
2014-12-17 |
2019-02-21 |
Zenith Epigenetics Ltd. |
Substituted bicyclic compounds as bromodomain inhibitors
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN107148417B
(zh)
|
2014-12-18 |
2020-09-08 |
豪夫迈·罗氏有限公司 |
苯并氮杂*磺酰胺化合物
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
AR103222A1
(es)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
PL410665A1
(pl)
|
2014-12-29 |
2016-07-04 |
Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością |
Inhibitory arginazy oraz ich zastosowania terapeutyczne
|
CN105732635A
(zh)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
一类Toll样受体7激动剂
|
US9518057B2
(en)
|
2014-12-30 |
2016-12-13 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis B infections
|
MA41291A
(fr)
|
2014-12-30 |
2017-11-07 |
Forma Therapeutics Inc |
Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
|
JP6506845B2
(ja)
|
2014-12-30 |
2019-04-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
CN107109497A
(zh)
|
2014-12-31 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
|
WO2016106626A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
|
WO2016106625A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Btk inhibitors
|
WO2016106624A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Tertiary alcohol imidazopyrazine btk inhibitors
|
WO2016106623A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Benzamide imidazopyrazine btk inhibitors
|
WO2016106652A1
(en)
|
2014-12-31 |
2016-07-07 |
Merck Sharp & Dohme Corp. |
Biarylether imidazopyrazine btk inhibitors
|
EP3042903B1
(en)
|
2015-01-06 |
2019-08-14 |
Impetis Biosciences Ltd. |
Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
CN107208102B
(zh)
|
2015-01-27 |
2021-07-06 |
豪夫迈·罗氏有限公司 |
重组hbv cccdna、其产生方法及其用途
|
EA032530B1
(ru)
|
2015-01-28 |
2019-06-28 |
Байер Фарма Акциенгезельшафт |
4h-пирроло[3,2-c]пиридин-4-оновые производные
|
WO2016126460A2
(en)
|
2015-02-06 |
2016-08-11 |
Proteq Technologies Llc |
Electrochromic devices
|
WO2016128335A1
(en)
|
2015-02-11 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
CN104878084B
(zh)
|
2015-03-04 |
2018-01-09 |
上海市杨浦区中心医院 |
检测奥沙利铂对于结直肠癌有效性的试剂盒
|
PT3097102T
(pt)
|
2015-03-04 |
2018-01-22 |
Gilead Sciences Inc |
Compostos de 4,6-diamino-pirido[3,2-d]pirimidina que modulam recetor do tipo toll
|
CR20170394A
(es)
|
2015-03-06 |
2017-09-25 |
Hoffmann La Roche |
Compuestos de dicarboxamida de benzazepinas
|
WO2016142894A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
SG11201706901TA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
Therapeutic cyclic compounds as immunomodulators
|
CA3220902A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
MX2017011614A
(es)
|
2015-03-10 |
2018-03-23 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores.
|
US10646475B2
(en)
|
2015-03-10 |
2020-05-12 |
The Trustees Of Princeton University |
SHMT inhibitors
|
CN107427476A
(zh)
|
2015-03-10 |
2017-12-01 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物
|
GB201504314D0
(en)
|
2015-03-13 |
2015-04-29 |
Univ Dundee |
Small molecules
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN108601764A
(zh)
|
2015-03-18 |
2018-09-28 |
阿尔维纳斯股份有限公司 |
用于靶蛋白的增强降解的化合物和方法
|
WO2016161145A1
(en)
|
2015-03-31 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Stk4 inhibitors for treatment of hematologic malignancies
|
WO2016161268A1
(en)
|
2015-04-01 |
2016-10-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antviral agents
|
WO2016161196A1
(en)
|
2015-04-03 |
2016-10-06 |
Mirna Therapeutics, Inc. |
Microrna-34 immunotherapy
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
WO2016162867A1
(en)
|
2015-04-08 |
2016-10-13 |
Efranat Ltd. |
Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
|
US10160755B2
(en)
|
2015-04-08 |
2018-12-25 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
JP6806342B2
(ja)
|
2015-04-10 |
2021-01-06 |
ベイジーン リミテッド |
インドールアミンとしての新規5又は8−置換イミダゾ[1,5−a]ピリジン類、及び/又はトリプトファン2,3−ジオキシゲナーゼ
|
EP3283472B1
(en)
|
2015-04-17 |
2021-04-14 |
Indiana University Research & Technology Corporation |
Hepatitis b viral assembly effectors
|
CA2982984C
(en)
|
2015-04-20 |
2023-10-17 |
Effector Therapeutics, Inc. |
Inhibitors of immune checkpoint modulators for use in treating cancer and infections
|
AU2016257772B2
(en)
|
2015-05-01 |
2022-06-02 |
Griffith University |
Diagnostic methods
|
JP6462155B2
(ja)
|
2015-05-04 |
2019-01-30 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
B型肝炎ウイルス感染症の治療用のHBsAg(HBV表面抗原)及びHBV DNA産生の阻害剤としてのテトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類
|
JP6806709B2
(ja)
|
2015-05-12 |
2021-01-06 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
|
CN108174607A
(zh)
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
US10196701B2
(en)
|
2015-06-01 |
2019-02-05 |
The Penn State Research Foundation |
Hepatitis B virus capsid assembly
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
|
SG10202105964RA
(en)
|
2015-06-25 |
2021-07-29 |
Univ Health Network |
Hpk1 inhibitors and methods of using same
|
US20160376864A1
(en)
|
2015-06-29 |
2016-12-29 |
Cameron International Corporation |
Apparatus and method for distributing fluids to a wellbore
|
WO2017001307A1
(en)
|
2015-06-30 |
2017-01-05 |
F. Hoffmann-La Roche Ag |
Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
|
GB201511477D0
(en)
|
2015-06-30 |
2015-08-12 |
Redx Pharma Plc |
Antiviral compounds
|
BR112017028456A2
(pt)
|
2015-07-02 |
2018-08-28 |
Glaxosmithkline Ip Dev Ltd |
composto, e, método de prevenção e/ou tratamento de hiv
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
WO2017007701A1
(en)
|
2015-07-07 |
2017-01-12 |
Merck Sharp & Dohme Corp. |
Antiviral phosphodiamide compounds
|
EP3325477B1
(en)
|
2015-07-21 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
CN107820496B
(zh)
|
2015-07-27 |
2020-11-03 |
豪夫迈·罗氏有限公司 |
用于治疗和预防乙型肝炎病毒感染的新的四环4-氧代-吡啶-3-甲酸衍生物
|
WO2017017043A1
(en)
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
BR112018001640A2
(pt)
|
2015-07-29 |
2018-09-18 |
Novartis Ag |
combinação de antagonista da pd-1 com um inibidor de egfr
|
US20180230545A1
(en)
|
2015-08-06 |
2018-08-16 |
Stichting Katholieke Universiteit |
Method for the prediction of progression of bladder cancer
|
AR105643A1
(es)
|
2015-08-10 |
2017-10-25 |
Merck Sharp & Dohme |
COMPUESTOS ANTIVIRALES DE FOSFODIAMIDA DE ÉSTER DE b-AMINOÁCIDO
|
EP3344644A4
(en)
|
2015-08-13 |
2019-02-27 |
Merck Sharp & Dohme Corp. |
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
|
WO2017034986A1
(en)
|
2015-08-21 |
2017-03-02 |
University Of Kansas |
Human tlr8-selective agonists
|
WO2017038909A1
(en)
|
2015-08-28 |
2017-03-09 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
EP3344622B1
(en)
|
2015-08-31 |
2021-07-07 |
3M Innovative Properties Company |
Guanidine substituted, fused 1h-imidazo[4,5-c]pyridine compounds useful in the treatment of viral and neoplastic diseases
|
TW201720802A
(zh)
|
2015-09-15 |
2017-06-16 |
艾森伯利生物科學公司 |
B型肝炎核心蛋白質調節劑
|
WO2017046112A1
(en)
|
2015-09-17 |
2017-03-23 |
F. Hoffmann-La Roche Ag |
Sulfinylphenyl or sulfonimidoylphenyl benzazepines
|
JP6856900B2
(ja)
|
2015-09-17 |
2021-04-14 |
国立大学法人富山大学 |
トール様受容体7またはトール様受容体9の活性化阻害剤
|
KR20180051625A
(ko)
|
2015-09-17 |
2018-05-16 |
노파르티스 아게 |
증진된 효능을 갖는 car t 세포 요법
|
FR3041639B1
(fr)
|
2015-09-30 |
2019-01-25 |
Les Laboratoires Servier |
NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
|
FR3041640B1
(fr)
|
2015-09-30 |
2019-05-17 |
Les Laboratoires Servier |
NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
|
WO2017061466A1
(ja)
|
2015-10-05 |
2017-04-13 |
富山化学工業株式会社 |
抗b型肝炎ウイルス剤
|
WO2017061532A1
(ja)
|
2015-10-07 |
2017-04-13 |
大日本住友製薬株式会社 |
ピリミジン化合物
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
TW201718581A
(zh)
|
2015-10-19 |
2017-06-01 |
英塞特公司 |
作為免疫調節劑之雜環化合物
|
CA3002236A1
(en)
|
2015-10-28 |
2017-05-04 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
EP3370699A1
(en)
|
2015-11-04 |
2018-09-12 |
Incyte Corporation |
Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
|
UA121345C2
(uk)
|
2015-11-05 |
2020-05-12 |
Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. |
7-(тіазол-5-іл)піролопіримідин як агоніст рецептора tlr7
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
WO2017087723A1
(en)
|
2015-11-19 |
2017-05-26 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
TWI763641B
(zh)
|
2015-11-19 |
2022-05-11 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
MX363780B
(es)
|
2015-12-03 |
2019-04-03 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
|
US10745428B2
(en)
|
2015-12-10 |
2020-08-18 |
Idenix Pharmaceuticals Llc |
Antiviral phosphodiamide prodrugs of tenofovir
|
WO2017106740A1
(en)
|
2015-12-16 |
2017-06-22 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
ITUB20159605A1
(it)
|
2015-12-17 |
2017-06-17 |
Alda S R L |
Kinase and ubiquitin ligase inhibitors and uses thereof
|
EP3390389B1
(en)
|
2015-12-17 |
2021-05-19 |
Merck Patent GmbH |
Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
|
TWI767896B
(zh)
|
2015-12-22 |
2022-06-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
CN116334113A
(zh)
|
2016-01-08 |
2023-06-27 |
加利福尼亚大学董事会 |
有条件活性的异二聚体多肽及其使用方法
|
WO2017140821A1
(en)
|
2016-02-19 |
2017-08-24 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
US20190091256A1
(en)
|
2016-03-02 |
2019-03-28 |
Beth Israel Deaconess Medical Center |
Therapeutic targets for lin-28-expressing cancers
|
WO2017156454A1
(en)
|
2016-03-10 |
2017-09-14 |
The Regents Of The University Of California |
Anti-cancer and splce modulating compounds and methods
|
KR102530488B1
(ko)
|
2016-03-18 |
2023-05-08 |
이뮨 센서, 엘엘씨 |
사이클릭 디-뉴클레오티드 화합물 및 사용 방법
|
EP3433249B1
(en)
|
2016-03-21 |
2022-11-09 |
Council Of Scientific & Industrial Research |
Blocking toll-like receptor 9 signaling with small molecule antagonist
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP7041070B2
(ja)
|
2016-04-15 |
2022-03-23 |
エピザイム,インコーポレイティド |
Ehmt1およびehmt2阻害剤としてのアミン置換アリールまたはヘテロアリール化合物
|
US10533007B2
(en)
|
2016-04-19 |
2020-01-14 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
US10556903B2
(en)
|
2016-04-19 |
2020-02-11 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
WO2017186711A1
(en)
|
2016-04-25 |
2017-11-02 |
Invivogen |
Novel complexes of immunostimulatory compounds, and uses thereof
|
US20170320875A1
(en)
|
2016-05-06 |
2017-11-09 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
PL3453707T3
(pl)
|
2016-05-06 |
2022-06-13 |
Shanghai De Novo Pharmatech Co., Ltd. |
Pochodna benzazepiny, sposób wytwarzania, kompozycja farmaceutyczna i jej zastosowanie
|
CN109153682B
(zh)
|
2016-05-20 |
2021-05-25 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
|
EP3464274B1
(en)
|
2016-05-23 |
2020-05-27 |
H. Hoffnabb-La Roche Ag |
Benzazepine dicarboxamide compounds with secondary amide function
|
CN109153648B
(zh)
|
2016-05-23 |
2022-07-22 |
豪夫迈·罗氏有限公司 |
具有叔酰胺官能团的苯并氮杂卓二甲酰胺化合物
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017202798A1
(en)
|
2016-05-26 |
2017-11-30 |
F. Hoffmann-La Roche Ag |
Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
|
WO2017211791A1
(en)
|
2016-06-07 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
CN109843296A
(zh)
|
2016-06-10 |
2019-06-04 |
英安塔制药有限公司 |
乙型肝炎抗病毒药剂
|
CN109311851B
(zh)
|
2016-06-12 |
2021-08-10 |
豪夫迈·罗氏有限公司 |
二氢嘧啶基苯并氮杂䓬甲酰胺化合物
|
CA2968836A1
(en)
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
US10870647B2
(en)
|
2016-06-20 |
2020-12-22 |
Daegu-Gyeongbuk Medical Innovation Foundation |
Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer
|
AU2017281285C1
(en)
|
2016-06-20 |
2022-05-12 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017219931A1
(zh)
|
2016-06-22 |
2017-12-28 |
四川科伦博泰生物医药股份有限公司 |
二氢蝶啶酮类衍生物、其制备方法及其用途
|
KR101789430B1
(ko)
|
2016-06-28 |
2017-10-25 |
동국대학교 산학협력단 |
Smo 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
|
CA3029688A1
(en)
|
2016-06-29 |
2018-01-04 |
Novira Therapeutics, Inc. |
Oxadiazepinone derivatives and their use in the treatment of hepatitis b infections
|
US10071079B2
(en)
|
2016-06-29 |
2018-09-11 |
Bristol-Myers Squibb Company |
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
|
EP3478686B1
(en)
|
2016-06-29 |
2020-04-15 |
H. Hoffnabb-La Roche Ag |
Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
CA3029566A1
(en)
|
2016-06-29 |
2018-01-04 |
Novira Therapeutics, Inc. |
Diazepinone derivatives and their use in the treatment of hepatitis b infections
|
EP3478680B1
(en)
|
2016-06-29 |
2020-04-22 |
H. Hoffnabb-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
|
KR102468272B1
(ko)
|
2016-06-30 |
2022-11-18 |
삼성전자주식회사 |
음향 출력 장치 및 그 제어 방법
|
JP6301402B2
(ja)
|
2016-07-01 |
2018-03-28 |
日新製鋼株式会社 |
フェライト系ステンレス鋼板およびその製造方法
|
CN109476675B
(zh)
|
2016-07-01 |
2022-12-09 |
爱尔兰詹森科学公司 |
用于治疗病毒性感染的二氢吡喃并嘧啶衍生物
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CA3029991A1
(en)
|
2016-07-08 |
2018-01-11 |
Bristol-Myers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
WO2018011160A1
(en)
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
WO2018011163A1
(en)
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
EP3484885B1
(en)
|
2016-07-14 |
2020-03-04 |
H. Hoffnabb-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
CN109476659B
(zh)
|
2016-07-14 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
用于治疗感染性疾病的新的四氢吡唑并吡啶化合物
|
US20180016260A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2018019297A1
(zh)
|
2016-07-29 |
2018-02-01 |
银杏树药业(苏州)有限公司 |
异喹啉酮类化合物及其制备抗病毒药物的应用
|
EP3490987B1
(en)
|
2016-07-29 |
2022-09-21 |
Guangzhou Lupeng Pharmaceutical Company Ltd. |
Novel therapeutic agents for the treatment of hbv infection
|
EA038972B1
(ru)
|
2016-07-30 |
2021-11-16 |
Бристол-Маерс Сквибб Компани |
Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9
|
CA3030773A1
(en)
|
2016-08-03 |
2018-02-08 |
Arising International, Inc. |
Symmetric or semi-symmetric compounds useful as immunomodulators
|
CN109689059A
(zh)
|
2016-08-24 |
2019-04-26 |
豪夫迈·罗氏有限公司 |
Hbv衣壳组装抑制剂和核苷或核苷酸类似物的组合疗法
|
AU2017314909B2
(en)
|
2016-08-26 |
2020-01-02 |
Solventum Intellectual Properties Company |
Fused [1,2]Imidazo[4,5-c] ring compounds substituted with guanidino groups
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
AU2017318601B2
(en)
|
2016-09-02 |
2020-09-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
WO2018043747A1
(ja)
|
2016-09-05 |
2018-03-08 |
国立大学法人京都大学 |
抗b型肝炎ウイルス剤
|
US11274115B2
(en)
|
2016-09-07 |
2022-03-15 |
Glaxosmithkline Biological Sa |
Imidazoquinoline derivatives and their use in therapy
|
US10660877B2
(en)
|
2016-09-09 |
2020-05-26 |
Bristol-Myers Squibb Company |
Pyridyl substituted indole compounds
|
EP3510032B1
(en)
|
2016-09-09 |
2022-07-06 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
TWI670266B
(zh)
|
2016-09-09 |
2019-09-01 |
大陸商浙江海正藥業股份有限公司 |
二氫嘧啶類化合物及其製備方法和用途
|
WO2018049152A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
PE20190732A1
(es)
|
2016-09-09 |
2019-05-23 |
Novartis Ag |
Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
|
WO2018051255A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
RS62410B1
(sr)
|
2016-10-04 |
2021-10-29 |
Merck Sharp & Dohme |
Benzo[b]tiofenska jedinjenja kao agonisti sting
|
EP3523314A1
(de)
|
2016-10-07 |
2019-08-14 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
US9725769B1
(en)
|
2016-10-07 |
2017-08-08 |
Oncology Venture ApS |
Methods for predicting drug responsiveness in cancer patients
|
SG10202010584XA
(en)
|
2016-10-20 |
2020-12-30 |
Aurigene Discovery Tech Ltd |
Dual inhibitors of vista and pd-1 pathways
|
WO2018080903A1
(en)
|
2016-10-26 |
2018-05-03 |
Merck Sharp & Dohme Corp. |
Antiviral aryl-amide phosphodiamide compounds
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
WO2018078149A1
(en)
|
2016-10-31 |
2018-05-03 |
F. Hoffmann-La Roche Ag |
Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
|
KR102526034B1
(ko)
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
US11084818B2
(en)
|
2016-11-11 |
2021-08-10 |
Hepo Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
|
WO2018089695A1
(en)
|
2016-11-11 |
2018-05-17 |
Dynavax Technologies Corporation |
Toll-like receptor antagonist compounds and methods of use
|
WO2018089212A1
(en)
|
2016-11-11 |
2018-05-17 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
CN108884092B
(zh)
|
2016-11-28 |
2021-06-29 |
江苏恒瑞医药股份有限公司 |
吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
|
EP3548479A1
(en)
|
2016-11-30 |
2019-10-09 |
ARIAD Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
RU2019122602A
(ru)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
|
KR102599339B1
(ko)
|
2016-12-20 |
2023-11-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 화합물
|
JP2020503303A
(ja)
|
2016-12-20 |
2020-01-30 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
がんの処置のための環状ジヌクレオチドstingアゴニスト
|
JP2020504734A
(ja)
|
2016-12-22 |
2020-02-13 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ウイルス性ベンジル−アミンホスホジアミド化合物
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
TWI808955B
(zh)
|
2016-12-22 |
2023-07-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
BR112019013017A2
(pt)
|
2016-12-22 |
2020-01-14 |
Idenix Pharmaceuticals Llc |
compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
|
MA47120A
(fr)
|
2016-12-22 |
2021-04-28 |
Incyte Corp |
Dérivés pyridine utilisés en tant qu'immunomodulateurs
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
US20180179202A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
US20180228786A1
(en)
*
|
2017-02-15 |
2018-08-16 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
PT3600309T
(pt)
|
2017-03-28 |
2022-10-03 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças hepáticas
|
EP3601284B1
(en)
*
|
2017-03-30 |
2023-12-27 |
F. Hoffmann-La Roche AG |
Naphthyridines as inhibitors of hpk1
|
BR112019019555A2
(pt)
|
2017-03-30 |
2020-04-22 |
Hoffmann La Roche |
composto de fórmula i, composição farmacêutica, método de inibição de hpk1, método para melhorar uma resposta imune, método para tratar um distúrbio e uso do composto
|
CA3064975A1
(en)
|
2017-05-26 |
2018-11-29 |
Glenmark Pharmaceuticals S.A. |
Novel inhibitors of map4k1
|
WO2018228923A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
|
EP3638669A1
(en)
|
2017-06-13 |
2020-04-22 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
CA3074381A1
(en)
|
2017-06-13 |
2018-12-20 |
Bayer Pharma Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
WO2019027987A2
(en)
|
2017-07-31 |
2019-02-07 |
The Johns Hopkins University |
COMPOSITIONS AND METHODS FOR TARGETING MASAS TO TREAT CANCERS WITH SPLICE COMPLEX MUTATIONS
|
WO2019051199A1
(en)
|
2017-09-08 |
2019-03-14 |
Incyte Corporation |
6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
CN109721620B
(zh)
|
2017-10-27 |
2022-05-13 |
药捷安康(南京)科技股份有限公司 |
Hpk1抑制剂及其用途
|
AU2018360559A1
(en)
|
2017-10-31 |
2020-05-07 |
Eisai R&D Management Co., Ltd. |
Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
|
US11166959B2
(en)
|
2017-11-06 |
2021-11-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as HPK1 inhibitors
|
EP3842433B1
(en)
|
2018-01-19 |
2023-11-01 |
Medshine Discovery Inc. |
Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
CA3091517A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
WO2019200120A1
(en)
|
2018-04-11 |
2019-10-17 |
Lycera Corporation |
Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
WO2019206049A1
(en)
|
2018-04-25 |
2019-10-31 |
Zhuhai Yufan Biotechnologies Co., Ltd |
Hpk1 inhibitors, preparation method and application thereof
|
CN108823307B
(zh)
|
2018-05-17 |
2020-10-30 |
浙江大学 |
Pd‐l1剪接体b作为指导抗pd‐l1/pd1免疫治疗的用药的标志物的应用
|
TW202016109A
(zh)
|
2018-06-13 |
2020-05-01 |
英屬開曼群島商百濟神州有限公司 |
作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
|
CN112601584A
(zh)
|
2018-07-24 |
2021-04-02 |
豪夫迈·罗氏有限公司 |
异喹啉化合物及其用途
|
JP7386842B2
(ja)
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
EP3852752A1
(en)
|
2018-09-19 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
|
JP7433304B2
(ja)
|
2018-09-30 |
2024-02-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
シンノリン化合物および癌などのhpk1依存性障害の治療
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
JP2022504080A
(ja)
|
2018-10-03 |
2022-01-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
8-アミノイソキノリン化合物およびその使用
|
AU2019352075B2
(en)
|
2018-10-05 |
2022-07-21 |
Ichnos Sciences S.A. |
Indolinone compounds for use as MAP4K1 inhibitors
|
IL262658A
(en)
|
2018-10-28 |
2020-04-30 |
Memorial Sloan Kettering Cancer Center |
Prevention of age related clonal hematopoiesis and diseases associated therewith
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
CN113227089A
(zh)
|
2018-10-31 |
2021-08-06 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
WO2020103896A1
(en)
|
2018-11-22 |
2020-05-28 |
Beigene, Ltd. |
Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
|
MX2021006154A
(es)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
|
EP3894406A1
(en)
|
2018-12-11 |
2021-10-20 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
KR20210135244A
(ko)
|
2019-02-04 |
2021-11-12 |
스카이호크 테라퓨틱스, 인코포레이티드 |
스플라이싱을 조절하는 방법 및 조성물
|
EP3920917A4
(en)
|
2019-02-04 |
2022-09-28 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
|
WO2020163401A1
(en)
|
2019-02-05 |
2020-08-13 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
CN114007613A
(zh)
|
2019-02-05 |
2022-02-01 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
CN114007612A
(zh)
|
2019-02-05 |
2022-02-01 |
斯基霍克疗法公司 |
用于调节剪接的方法和组合物
|
EP3920928A4
(en)
|
2019-02-06 |
2022-09-28 |
Skyhawk Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
|
CN113939518A
(zh)
|
2019-03-15 |
2022-01-14 |
杭州英创医药科技有限公司 |
作为激酶抑制剂的稠合三环化合物
|
MA55478A
(fr)
|
2019-03-26 |
2022-02-09 |
Janssen Pharmaceutica Nv |
Inhibiteurs bicycliques de hpk1
|
TW202102488A
(zh)
|
2019-03-26 |
2021-01-16 |
比利時商健生藥品公司 |
Hpk1抑制劑
|
CA3132936A1
(en)
|
2019-04-09 |
2020-10-15 |
Maria Luisa PINEDA |
Cancer-specific molecules and methods of use thereof
|
TW202106877A
(zh)
|
2019-04-24 |
2021-02-16 |
美商斯托克治療公司 |
調節剪接及轉譯之方法及組合物
|
CA3137916A1
(en)
|
2019-05-06 |
2020-11-12 |
Ichan School Of Medicine At Mount Sinai |
Heterobifunctional compounds as degraders of hpk1
|
KR20200133188A
(ko)
|
2019-05-17 |
2020-11-26 |
보로노이바이오 주식회사 |
헤테로고리 융합 피리미딘 유도체 및 이의 용도
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
WO2020255022A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
|
AU2020298649A1
(en)
|
2019-07-04 |
2022-02-17 |
Regor Pharmaceuticals, Inc. |
HPK1 inhibitors and uses thereof
|
TW202116773A
(zh)
|
2019-07-04 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
作為HPK1抑制劑之吡咯并[2,3-b]吡及其用途
|
WO2021004547A1
(en)
|
2019-07-11 |
2021-01-14 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of hpk1
|
TW202116753A
(zh)
|
2019-07-11 |
2021-05-01 |
大陸商南京征祥醫藥有限公司 |
以噌啉作為hpk1的抑制劑
|
WO2021013083A1
(en)
|
2019-07-17 |
2021-01-28 |
Beigene, Ltd. |
Tricyclic compounds as hpk1 inhibitor and the use thereof
|
MX2022001562A
(es)
|
2019-08-06 |
2022-04-26 |
Incyte Corp |
Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220265864A1
(en)
|
2019-08-15 |
2022-08-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
|
WO2021032148A1
(en)
|
2019-08-21 |
2021-02-25 |
Beigene, Ltd. |
Aminopyrazine compounds as hpk1 inhibitor and the use thereof
|
WO2021046254A1
(en)
|
2019-09-04 |
2021-03-11 |
Exicure, Inc. |
Liposomal spherical nucleic acid (sna) constructs for splice modulation
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
CN112552293A
(zh)
|
2019-09-25 |
2021-03-26 |
珠海宇繁生物科技有限责任公司 |
一种protac小分子化合物及其应用
|
WO2021074279A1
(en)
|
2019-10-16 |
2021-04-22 |
Bayer Aktiengesellschaft |
Spiro-fused tricyclic map4k1 inhibitors
|
JP2023510918A
(ja)
|
2020-01-15 |
2023-03-15 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
CN113336747A
(zh)
|
2020-03-03 |
2021-09-03 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
WO2021213317A1
(zh)
|
2020-04-20 |
2021-10-28 |
微境生物医药科技(上海)有限公司 |
Hpk1抑制剂及其制备方法和用途
|
CN115698004A
(zh)
|
2020-05-01 |
2023-02-03 |
辉瑞公司 |
作为hpk1抑制剂的氮杂内酰胺化合物
|
KR20230008176A
(ko)
|
2020-05-06 |
2023-01-13 |
누릭스 테라퓨틱스 인코포레이티드 |
조혈 전구세포 키나아제의 이작용성 분해제 및 이의 치료적 용도
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
MX2022014168A
(es)
|
2020-05-11 |
2023-02-22 |
Univ Health Network |
Sal y formas de cristal de 4-amino-5-(6-(4-metilpiperazin-1-il)-ih benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona.
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
CN113797202A
(zh)
|
2020-06-16 |
2021-12-17 |
珠海宇繁生物科技有限责任公司 |
Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
|
CN113845531A
(zh)
|
2020-06-28 |
2021-12-28 |
四川科伦博泰生物医药股份有限公司 |
吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
|
CN116874503A
(zh)
|
2020-10-28 |
2023-10-13 |
杭州阿诺生物医药科技有限公司 |
一种高活性的hpk1激酶抑制剂
|
CN114437058A
(zh)
|
2020-10-30 |
2022-05-06 |
珠海宇繁生物科技有限责任公司 |
氘代hpk1激酶抑制剂及其制备方法和应用
|
CN114437074A
(zh)
|
2020-11-03 |
2022-05-06 |
北京伯汇生物技术有限公司 |
一种化合物、含该化合物的药物组合物及其用途
|
US20230406864A1
(en)
|
2020-11-09 |
2023-12-21 |
Merck Sharp & Dohme Llc |
7-azole substituted 2-aminoquinazoline inhibitors of hpk1
|
EP4240362A1
(en)
|
2020-11-09 |
2023-09-13 |
Merck Sharp & Dohme LLC |
Diaminopyrimidine carboxamide inhibitors of hpk1
|
WO2022098806A1
(en)
|
2020-11-09 |
2022-05-12 |
Merck Sharp & Dohme Corp. |
7-phenyl substituted 2-aminoquinazoline inhibitors of hpk1
|
CN116438172A
(zh)
|
2020-11-13 |
2023-07-14 |
南京红云生物科技有限公司 |
Hpk1激酶调节剂、其制备方法与应用
|
WO2022107919A1
(ko)
|
2020-11-19 |
2022-05-27 |
주식회사 보로노이 |
N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
|
CN114516857A
(zh)
|
2020-11-20 |
2022-05-20 |
深圳智药信息科技有限公司 |
Hpk1抑制剂及其用途
|
EP4253386A1
(en)
|
2020-11-24 |
2023-10-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Deuterium-modified thienopyridone compound
|
WO2022131741A1
(ko)
|
2020-12-14 |
2022-06-23 |
보로노이바이오 주식회사 |
아이소옥사졸리딘 유도체 화합물 및 이의 용도
|
CN114685489A
(zh)
|
2020-12-31 |
2022-07-01 |
江苏先声药业有限公司 |
多取代含氮杂环类化合物及其应用
|
CN114685490A
(zh)
|
2020-12-31 |
2022-07-01 |
江苏先声药业有限公司 |
吡咯并吡啶类化合物及其应用
|
CN114805330A
(zh)
|
2021-01-22 |
2022-07-29 |
苏州信诺维医药科技股份有限公司 |
Hpk1抑制剂、其制备方法、药物组合物及其应用
|
EP4288437A1
(en)
|
2021-02-05 |
2023-12-13 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
CN114907374A
(zh)
|
2021-02-07 |
2022-08-16 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
CN114907375A
(zh)
|
2021-02-07 |
2022-08-16 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
CN116848119A
(zh)
|
2021-02-08 |
2023-10-03 |
杭州中美华东制药有限公司 |
一种吡咯并哒嗪类化合物及其制备方法和用途
|
CN114907377A
(zh)
|
2021-02-10 |
2022-08-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类化合物、其制备方法及其在医药上的应用
|
CN116848113A
(zh)
|
2021-02-10 |
2023-10-03 |
南京再明医药有限公司 |
作为hpk1抑制剂的双环类化合物及其应用
|
US20230096641A1
(en)
|
2021-02-12 |
2023-03-30 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
CN116981661A
(zh)
|
2021-03-03 |
2023-10-31 |
劲方医药科技(上海)有限公司 |
稠环取代的六元杂环化合物及其制法和用途
|
JP2024509192A
(ja)
|
2021-03-05 |
2024-02-29 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
WO2022188735A1
(en)
|
2021-03-08 |
2022-09-15 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as hpk1 inhibitors
|
CN116888127A
(zh)
|
2021-03-10 |
2023-10-13 |
轩竹生物科技股份有限公司 |
三并环类hpk1抑制剂及其用途
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
CN113861188B
(zh)
|
2021-08-23 |
2023-02-28 |
杭州医学院 |
吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用
|
CN114315796B
(zh)
|
2021-12-30 |
2024-03-26 |
中国药科大学 |
用作hpk1激酶抑制剂的化合物及其制备方法和应用
|
CN114853730B
(zh)
|
2022-05-27 |
2024-03-26 |
中国药科大学 |
用作hpk1激酶抑制剂的化合物及其制备方法和应用
|
CN114940683B
(zh)
|
2022-07-26 |
2023-01-17 |
轩竹(北京)医药科技有限公司 |
Hpk1抑制剂及其用途
|